Veracyte (NASDAQ:VCYT) Shares Gap Up Following Strong Earnings

Key Points

• Veracyte shares jumped premarket after a Q1 beat—EPS of $0.52 vs. $0.34 expected and revenue of $139.1M (up 21.5% YoY), opening at $39 from a prior close of $32.97.
• The company raised FY26 revenue guidance to $582M–$592M, above Street estimates, reinforcing a beat-and-raise narrative.
• Analysts imply roughly 39% upside on average, and investors are watching commercial catalysts—TrueMRD rollout and Decipher data at AUA 2026—that could further lift the stock.

Veracyte, Inc. (NASDAQ:VCYT - Get Free Report)'s share price gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $32.97, but opened at $39.00. Veracyte shares last traded at $38.6710, with a volume of 225,313 shares traded.

The biotechnology company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.34 by $0.18. The company had revenue of $139.07 million during the quarter, compared to analyst estimates of $130.36 million. Veracyte had a return on equity of 8.05% and a net margin of 12.83%.The business's revenue was up 21.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.31 earnings per share.

More Veracyte News

Here are the key news stories impacting Veracyte this week:

• Positive Sentiment: Q1 beat — Veracyte reported $0.52 EPS vs. $0.34 consensus and revenue of $139.1M (vs. $130.4M expected), with revenue +21.5% YoY and improved margins; management highlighted volume growth in Decipher and Afirma. Veracyte Announces First Quarter 2026 Financial Results
• Positive Sentiment: Raised FY26 revenue guide — Veracyte set revenue guidance of $582M–$592M, above the Street consensus (~$576.5M); that guide lift reinforces the beat-and-raise narrative. Veracyte Q1 Press Materials (slide deck / release)
• Positive Sentiment: Analyst upside — Wall Street price-targets imply material upside (~39% median/average in coverage notes) following stronger results and revisions. This can amplify buying interest. Wall Street Analysts Think Veracyte Could Surge 39.16%
• Positive Sentiment: Product/clinical catalysts — Investors are watching rollout details for TrueMRD (minimal residual disease) as a potential growth driver; successful launch/clarity on timing/pricing could further lift the stock. Veracyte earnings loom: Investors watch for TrueMRD launch details
• Positive Sentiment: Pipeline data ahead — New Decipher bladder and prostate data scheduled for AUA 2026 could provide incremental clinical validation and commercial lift for Decipher franchise. A Look At Veracyte Valuation As New Decipher Data Heads To AUA 2026
• Neutral Sentiment: Call/transcript details — Full Q1 earnings call and transcripts are available for deeper read on product cadence, margin drivers, and timing for TrueMRD commercialization; these details will shape near-term guidance confidence. Q1 2026 Earnings Call Transcript

Analysts Set New Price Targets

VCYT has been the subject of several analyst reports. Guggenheim reduced their price objective on Veracyte from $50.00 to $45.00 and set a "buy" rating for the company in a research report on Monday, March 30th. Zacks Research downgraded Veracyte from a "strong-buy" rating to a "hold" rating in a research report on Thursday, March 12th. UBS Group reiterated a "buy" rating on shares of Veracyte in a research report on Monday, January 12th. Needham & Company LLC reiterated a "buy" rating and set a $48.00 price objective on shares of Veracyte in a research report on Wednesday, April 1st. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Veracyte in a research report on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $44.17.

Insider Transactions at Veracyte

In other Veracyte news, insider John Leite sold 5,260 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $35.19, for a total value of $185,099.40. Following the completion of the sale, the insider directly owned 107,580 shares in the company, valued at $3,785,740.20. This represents a 4.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Rebecca Chambers sold 18,341 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $36.14, for a total value of $662,843.74. Following the completion of the sale, the chief financial officer owned 131,196 shares of the company's stock, valued at $4,741,423.44. This trade represents a 12.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 75,782 shares of company stock valued at $2,722,097. 1.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Veracyte

A number of institutional investors have recently added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund lifted its position in Veracyte by 2.3% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 18,100 shares of the biotechnology company's stock worth $762,000 after purchasing an additional 400 shares during the period. Arizona State Retirement System lifted its position in shares of Veracyte by 1.8% during the 3rd quarter. Arizona State Retirement System now owns 23,158 shares of the biotechnology company's stock valued at $795,000 after acquiring an additional 419 shares during the last quarter. State of Alaska Department of Revenue boosted its stake in shares of Veracyte by 1.3% during the 4th quarter. State of Alaska Department of Revenue now owns 44,264 shares of the biotechnology company's stock worth $1,862,000 after acquiring an additional 552 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of Veracyte by 0.8% during the 2nd quarter. California State Teachers Retirement System now owns 71,095 shares of the biotechnology company's stock worth $1,922,000 after acquiring an additional 566 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC boosted its stake in shares of Veracyte by 7.9% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 7,894 shares of the biotechnology company's stock worth $332,000 after acquiring an additional 576 shares in the last quarter.

Veracyte Stock Performance

The firm has a market capitalization of $3.14 billion, a P/E ratio of 46.77 and a beta of 1.89. The firm has a 50 day moving average price of $33.33 and a two-hundred day moving average price of $38.16.

Veracyte Company Profile

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte's proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company's flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.